Drug Trial Radar · NCT00685165
Fasted Bioequivalence Study of Primidone Tablets and Mysoline Tablets
Last checked: Nov 19, 2026Latest source record: Jan 20, 2010 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
22
Actual
Start
May 2004
Primary completion
Jun 2004
Study completion Jun 2004
Sponsor
- Lead sponsor
- Mutual Pharmaceutical Company, Inc.Industry
- Sponsor type
- Industry
- First posted
- May 28, 2008
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Crossover
- Masking
- None
- Primary purpose
- Basic science
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this study is to compare the bioequivalence of a test formulation of primidone tablets to an equivalent oral dose of the commercially available Mysoline®(primidone tablets) in adult subjects under fasting conditions.
Conditions
- Therapeutic Equivalency
Interventions
Primidone 50 mg TabletDrug
50 mg tablet administered after an overnight fast of at least 10 hours.
Primidone (Mysoline®) 50 mg TabletDrug
50 mg tablet administered after an overnight fast of at least 10 hours.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Maximum Plasma Concentration (Cmax)Time frame: serial pharmacokinetic plasma concentrations were drawn prior to dose administration (0 hour) and at 0.33, 0.67, 1, 1.33, 1.67, 2, 2.33, 2.67, 3, 3.5, 4, 4.5, 5, 6, 8, 12, 18, 24, 36, 48, 60 and 72 hours after drug administration.
- Area Under the Concentration Versus Time Curve From Time 0 to Time t [AUC(0-t)]Time frame: serial pharmacokinetic plasma concentrations were drawn prior to dose administration (0 hour) and at 0.33, 0.67, 1, 1.33, 1.67, 2, 2.33, 2.67, 3, 3.5, 4, 4.5, 5, 6, 8, 12, 18, 24, 36, 48, 60 and 72 hours after drug administration.
- Area Under the Concentration Versus Time Curve From Time 0 Extrapolated to Infinity [AUC(0-∞)]Time frame: serial pharmacokinetic plasma concentrations were drawn prior to dose administration (0 hour) and at 0.33, 0.67, 1, 1.33, 1.67, 2, 2.33, 2.67, 3, 3.5, 4, 4.5, 5, 6, 8, 12, 18, 24, 36, 48, 60 and 72 hours after drug administration.
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.